165 related articles for article (PubMed ID: 6413369)
21. Evidence-based focused review of management of hyperviscosity syndrome.
Stone MJ; Bogen SA
Blood; 2012 Mar; 119(10):2205-8. PubMed ID: 22147890
[No Abstract] [Full Text] [Related]
22. [Blood diseases].
Bottura C
Prensa Med Argent; 1966 Sep; 53(39):2358-69. PubMed ID: 4969976
[No Abstract] [Full Text] [Related]
23. [Extracorporeal methods of therapy in lymphatic tumors].
Ryzhko VV; Andreeva NE; Gorodetskiĭ VM; Konovalova VI; Aleksanian MZh; Sinitsina TV
Ter Arkh; 1990; 62(7):59-63. PubMed ID: 2123573
[TBL] [Abstract][Full Text] [Related]
24. Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases.
Mód A; Füst G; Harsányi V; Natonek K; Poros A; Szabó J; Hollán SR
Haematologia (Budap); 1981; 14(1):49-56. PubMed ID: 6454615
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of hematologic diseases with alpha interferon].
Castaigne S
Bull Cancer; 1988; 75(9):859-62. PubMed ID: 3207895
[TBL] [Abstract][Full Text] [Related]
26. [Effect of intensive plasmapheresis on the "syndrome of increased viscosity" and blood coagulation system in Waldenstrom's macroglobulinemia].
Mokeeva RA; Zhuravlev VS
Probl Gematol Pereliv Krovi; 1969 Mar; 14(3):8-16. PubMed ID: 4981700
[No Abstract] [Full Text] [Related]
27. One year review of the blood cell separator programme.
Tan YO; Kueh YK; Suri R; Oon CJ; Ng HW; Goh CN; Ong YW
Ann Acad Med Singap; 1981 Jul; 10(3):394-7. PubMed ID: 7332308
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic value of the cell separator. Review and case reports].
Rossi PL
Minerva Med; 1979 Apr; 70(18):1289-98. PubMed ID: 450268
[TBL] [Abstract][Full Text] [Related]
29. Correction of hyperviscosity by apheresis.
Zarkovic M; Kwaan HC
Semin Thromb Hemost; 2003 Oct; 29(5):535-42. PubMed ID: 14631553
[TBL] [Abstract][Full Text] [Related]
30. Compelling splenectomy in medically compromised patients.
Bergin JJ; Zuck TF; Miller RE
Ann Surg; 1973 Dec; 178(6):761-8. PubMed ID: 4519051
[No Abstract] [Full Text] [Related]
31. [Immunomodulation with apheresis technics].
Liebert A; Quietzsch D; Zimmermann S
Allerg Immunol (Leipz); 1986; 32(1):5-18. PubMed ID: 2940851
[TBL] [Abstract][Full Text] [Related]
32. Applications and limitations of hemapheresis.
Silvergleid AJ
Annu Rev Med; 1983; 34():69-89. PubMed ID: 6344778
[TBL] [Abstract][Full Text] [Related]
33. Pheresis therapy: patient care.
Rossman M; Slavin R; Taft EG
Am J Nurs; 1977 Jul; 77(7):1135-41. PubMed ID: 406786
[No Abstract] [Full Text] [Related]
34. [Interferon therapy in hematologic neoplasms].
Schwarzinger I; Bettelheim P; Lechner K
Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of plasmapheresis on the PF-0.5 blood separator in patients with paraproteinemic hemoblastoses].
Abdullaev OM; Postnikov AA; Prigozhina TA; Likhovetskaia ZM; Mokeeva RA
Ter Arkh; 1987; 59(10):77-81. PubMed ID: 2448887
[TBL] [Abstract][Full Text] [Related]
36. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation.
Reinhart WH; Lutolf O; Nydegger UR; Mahler F; Straub PW
J Lab Clin Med; 1992 Jan; 119(1):69-76. PubMed ID: 1727909
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic apheresis: when things go wrong.
Torloni AS; Lumadue J; Zubair A
J Clin Apher; 2012; 27(3):168-71. PubMed ID: 22504899
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome.
Blum W; Porcu P
Semin Thromb Hemost; 2007 Jun; 33(4):350-4. PubMed ID: 17525892
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic apheresis: where we've been and where we are going.
Vogler WR
Prog Clin Biol Res; 1982; 106():1-13. PubMed ID: 6757935
[TBL] [Abstract][Full Text] [Related]
40. Practical considerations for planning a therapeutic apheresis procedure.
Shelat SG
Am J Med; 2010 Sep; 123(9):777-84. PubMed ID: 20541168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
